Kashyap Patel, MD: COA's Goals for Its Biosimilars Committee

Kashyap Patel, MD, discusses the goals of the Community Oncology Alliance (COA) in forming its biosimilars committee.
May 27, 2019



Transcript:

Biosimilars are a totally new class of drug in the United States, and unlike generics, there's a complex science involved in developing biosimilars.

But there’s a tremendous knowledge gap between the providers. Multiple studies have shown that between 1 and 4 to 1 and 2 doctors are not familiar with the FDA pathway, which is 351(k) for the biosimilar.

So [the Community Oncology Alliance, COA] plays a central role in evaluating this knowledge gap and bridging that gap by bringing the evidence-based scientific education piece to all the stakeholders, which includes in patients, physicians, as well as providers.

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.